ALK IHC Scoring for Rapid NSCLC Treatment Response Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a specific, sensitive, and standardized assay to quickly and accurately identify non-small cell lung carcinoma (NSCLC) patients most likely to respond to anaplastic lymphoma kinase (ALK) inhibitor treatment, as current methods like FISH are time-consuming, expensive, and prone to false negatives.
Innovation Solution
A method using immunohistochemistry (IHC) with anti-ALK antibodies and scoring for strong granular cytoplasmic staining in tumor cells to determine ALK positivity, providing rapid, cost-effective, and unequivocal identification of NSCLC patients likely to respond to ALK inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If FISH assays are used to determine ALK status, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent employs immunohistochemistry (IHC) as a simpler, more accessible alternative to FISH assays. IHC uses standard pathology laboratory equipment and protocols that are already widely available, eliminating the need for specialized FISH technology infrastructure. This disposable-like approach to methodology replacement reduces complexity while maintaining diagnostic utility through standardized scoring systems.
Solution Approach 2:
The patent replaces the complex molecular cytogenetic FISH methodology with immunohistochemistry, which uses antibody-antigen binding mechanisms instead of fluorescent probe hybridization. This substitution simplifies the technical requirements while achieving comparable diagnostic accuracy for ALK status determination through well-established IHC staining and scoring protocols.
2Measurement precision
If FISH assays are used to determine ALK status, then measurement precision is improved, but loss of time increases
Solution Approach 1:
The patent utilizes tissue samples that have already been processed and prepared for routine pathology examination. By performing IHC on these pre-prepared samples using standard laboratory workflows, the method eliminates the need for separate, time-consuming FISH assay preparation steps, thereby reducing total testing time while maintaining diagnostic precision.
Solution Approach 2:
The patent changes the methodological parameter from FISH to IHC, which has different time requirements. IHC protocols are generally faster and more streamlined than FISH assays, allowing for quicker turnaround times in determining ALK status without sacrificing measurement precision through the use of validated scoring systems.
3Measurement precision
If FISH assays are used to determine ALK status, then measurement precision is improved, but ease of operation deteriorates
Solution Approach 1:
The patent leverages the universality of immunohistochemistry, which is a broadly applicable technique already integrated into routine pathology laboratories worldwide. This universal methodology can be performed by standard pathology personnel without requiring specialized FISH training or expertise, thereby improving ease of operation and accessibility while maintaining measurement precision through established IHC protocols.
Solution Approach 2:
The patent enables pathology laboratories to independently perform ALK status determination using their existing IHC capabilities and resources. This self-service approach eliminates the need for external FISH testing services or specialized equipment, allowing laboratories to autonomously identify ALK-positive patients using standard operating procedures and familiar techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IHC method offers high sensitivity and specificity in identifying ALK-positive NSCLC tumors, enabling accurate patient selection for ALK inhibitor treatment with reduced equivocal results and no pre-specified tumor cell content requirements.
Implementation Method 1
identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC)... a sample is labeled with an anti-ALK antibody
Data Source
AI summary
Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.